An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy thai adults

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4050-4057

  Pukrittayakamee, Sasithon ^a   Jittamala, Podjanee ^a   Stepniewska, Kasia ^a,b   Lindegardh, Niklas ^a,b   Chueasuwanchai, Sunee ^a   Leowattana, Wattana ^a   Phakdeeraj, Aphiradee ^a   Permpunpanich, Sutatip ^a   Hanpithakpong, Warunee ^a   Pan Ngum, Wirichada ^a   Fukuda, Caroline ^a   Panapipat, Salwaluk ^a   Singhasivanon, Pratap ^a   White, Nicholas J ^a,b   Day, Nicholas P J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; ZANAMIVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSELTAMIVIR; YOUNG ADULT; ZANAMIVIR;

EID: 80051810294     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00159-11     Document Type: Article

References (18)

1. Arya, V., W W Carter, and S M Robertson. 2010. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin. Pharmacol. Ther. 88:587-589.
2. Beigel, J H, et al. 2005. Current concepts-avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374-1385. (Pubitemid 41362705)
3. Brown, A N, et al. 2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob. Agents Chemother. 55:1747-1753.
4. Cass, L M R, C. Efthymiopoulos, and A. Bye. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36(Suppl. 1):1-11. (Pubitemid 29322452)
5. Daniel, M J, J M Barnett, and B A Pearson. 1999. The low potential for drug interactions with zanamivir. Clin. Pharmacokinet. 36(Suppl. 1):41-50. (Pubitemid 29322456)
6. De Jong, M D, et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672. (Pubitemid 41817715)
7. Food and Drug Administration. 2001. Guidance for industry: statistical approaches to establishing bioequivalence. FDA, Washington, DC.
8. Food and Drug Administration. 2003. Guidance for industry: bioavailability and bioequivalence, studies for orally administered drug products-general consideration. FDA, Washington, DC.
9. Gubareva, L V, M N Matrosovich, M K Brenner, R C Bethell, and R G Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
10. Hill, G., et al. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30:13-19. (Pubitemid 34016935)
11. Kiso, M., et al. 2004. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 364:759-765. (Pubitemid 39165094)
12. Lindegårdh, N., et al. 2007. Importance of collection tube during clinical studies of oseltamivir. Antimicrob. Agents Chemother. 51:1835-1836. (Pubitemid 46744167)
13. Lindegårdh, N., et al. 2007. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 859:74-83. (Pubitemid 47626090)
14. Lindegardh, N., et al. 2011. Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS. Bioanalysis 3:157-165.
15. Massarella, J W, et al. 2000. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J. Clin. Pharmacol. 40:836-843.
16. Moscona, A. 2005. Oseltamivir resistance-disabling our influenza defences. N. Engl. J. Med. 353:2633-2637.
17. Wattanagoon, Y., et al. 2009. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob. Agents Chemother. 53:945-952.
18. Wooldridge, J M 2002. Econometric analysis of cross section and panel data. Chapter 10. MIT Press, Cambridge, MA.